Protein-bound paclitaxel

Protein-bound paclitaxel
Combination of
PaclitaxelMitotic inhibitor
AlbuminDelivery vehicle
Clinical data
Trade namesAbraxane, others
AHFS/Drugs.comMonograph
MedlinePlusa619008
License data
Pregnancy
category
  • AU: D
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • CA: ℞-only[1]
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
 ☒NcheckY (what is this?)  (verify)

Protein-bound paclitaxel, also known as nanoparticle albumin–bound paclitaxel or nab-paclitaxel, is an injectable formulation of paclitaxel used to treat breast cancer, lung cancer and pancreatic cancer, among others. Paclitaxel kills cancer cells by preventing the normal breakdown of microtubules during cell division.[2][3][4] In this formulation, paclitaxel is bonded to albumin as a delivery vehicle.[5] It is manufactured and sold in the United States by Celgene under the trade name Abraxane where it is designated as an orphan drug as first-line treatment, in combination with gemcitabine, for the orphan disease "metastatic adenocarcinoma of the pancreas".[6]

This treatment was approved in the United States in 2005,[7] and the European Union in 2008, for breast cancer cases where cancer did not respond to other chemotherapy or has relapsed.[8][9] In 2012, the FDA widened the approved uses to include treatment for NSCLC.[3][10] In 2013, the FDA approved protein-bound paclitaxel for use in treating advanced pancreatic cancer as a less toxic (although less effective) alternative to FOLFIRINOX.[4]

  1. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  2. ^ "Definition of "protein-bound paclitaxel"". National Cancer Institute Dictionary of Cancer Terms. February 2, 2011.
  3. ^ a b "FDA approves Celgene's Abraxane for lung cancer". Reuters. October 12, 2012.
  4. ^ a b Pollack A (7 September 2013). "F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer". New York Times. Retrieved 6 September 2013.
  5. ^ "Paclitaxel Albumin-stabilized Nanoparticle Formulation". National Cancer Institute Drug Information. 2006.
  6. ^ "Abraxane". Orpha Net. 6 September 2013. Retrieved 20 July 2015.
  7. ^ Knapp A (27 August 2020). "The Inside Story Of Biotech's Barnum And His Covid Cures". Forbes. Retrieved 27 August 2020.
  8. ^ "FDA Approval for Nanoparticle Paclitaxel". National Cancer Institute Drug Information. 2006.
  9. ^ "Abraxane EPAR". European Medicines Agency (EMA). 9 March 2020. Retrieved 9 March 2020.
  10. ^ "Paclitaxel (Abraxane)". U.S. Food and Drug Administration. 11 October 2012. Retrieved 10 December 2012.